Compare · NYXH vs RMD
NYXH vs RMD
Side-by-side comparison of Nyxoah SA (NYXH) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NYXH and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $28.33B, about 463.4x NYXH ($61.1M).
- Over the past year, NYXH is down 80.1% and RMD is down 28.6% - RMD leads by 51.5 points.
- RMD has been more active in the news (7 items in the past 4 weeks vs 2 for NYXH).
- RMD has more recent analyst coverage (25 ratings vs 9 for NYXH).
- Company
- Nyxoah SA
- ResMed Inc.
- Price
- $1.41-3.77%
- $195.32+1.83%
- Market cap
- $61.1M
- $28.33B
- 1M return
- -13.27%
- -0.61%
- 1Y return
- -80.09%
- -28.59%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 2
- 7
- Recent ratings
- 9
- 25
Nyxoah SA
Nyxoah S.A., a health-technology company, focuses on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. It offers Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treast moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is based in Mont-Saint-Guibert, Belgium.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest NYXH
- SEC Form 6-K filed by Nyxoah SA
- Nyxoah Announces Preliminary Results for the Second Quarter of 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by Nyxoah SA
- Information on the total number of voting rights and shares
- Publication relating to transparency notifications
- SEC Form 6-K filed by Nyxoah SA
- Nyxoah to Host Investor Day in New York on July 8, 2026
- SEC Form SCHEDULE 13G filed by Nyxoah SA
- Invitation to attend the extraordinary shareholders’ meeting of the Company to be held on July 9, 2026
- Publication relating to transparency notifications
Latest RMD
- BetterInvesting™ Magazine Update on Broadridge Financial Resources Inc. (NYSE:BR) and ResMed Inc. (NYSE:RMD)
- ResMed downgraded by RBC Capital Mkts with a new price target
- ResMed downgraded by Citigroup with a new price target
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,090,771 worth of ResMed Common Stock (4,991 units at $218.55) as part of a pre-agreed trading plan (SEC Form 4)
- ResMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure
- Resmed Announces Agreement to Sell MatrixCare Business
- SEC Form 144 filed by ResMed Inc.
- Resmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026
- ResMed downgraded by Morgan Stanley with a new price target
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $968,064 worth of ResMed Common Stock (4,991 units at $193.96) as part of a pre-agreed trading plan, increasing direct ownership by 0.01% to 466,256 units (SEC Form 4)